Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema

Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema

Abstract Background Diabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity (BCVA). This study aimed to evaluate the...

Full description

Bibliographic Details
Main Authors: Verónica Castro-Navarro, Enrique Cervera-Taulet, Catalina Navarro-Palop, Clara Monferrer-Adsuara, Laura Hernández-Bel, Javier Montero-Hernández
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Ophthalmology
Subjects:
Diabetes
Macular edema
Corticoids
Dexamethasone implant
Ozurdex
Online Access:http://link.springer.com/article/10.1186/s12886-018-1022-9

Internet

http://link.springer.com/article/10.1186/s12886-018-1022-9

Similar Items